Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,709 shares of the biopharmaceutical company’s stock after acquiring an additional 215 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Gilead Sciences were worth $463,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new stake in Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences during the fourth quarter worth $31,000. Finally, Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $114.74 on Wednesday. The firm’s fifty day simple moving average is $98.28 and its 200 day simple moving average is $90.74. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $117.39. The firm has a market capitalization of $143.00 billion, a price-to-earnings ratio of 310.11, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.75%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 293,356 shares of company stock valued at $29,166,240. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Oppenheimer upped their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, BMO Capital Markets lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.76.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.